Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Takes Inspection Appeal To WHO

This article was originally published in PharmAsia News

Executive Summary

On the heels of signing two memoranda of understanding with China, the United States says it wants an international certification system for imported products. Health and Human Services Secretary Mike Leavitt signed the memoranda during a recent trip to China, requiring China to strengthen its own safety checks on drug supplies. Speaking to the annual assembly of the World Health Organization in Geneva, Leavitt said no nation could ensure the safety of imported products by inspecting at its borders. Instead, they rely on a "collaborative system of international standards and local controls." (Click here for more

You may also be interested in...



Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.

Hahn Praises CDRH Staff For Mitigating COVID-19 Deaths

The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel